Mealey's (August 5, 2020, 9:05 AM EDT) -- PHILADELPHIA — Drug maker Taro Pharmaceuticals U.S.A. Inc. on July 23 entered into a deferred prosecution agreement (DPA) with a U.S. attorney's office for two charges of criminal antitrust activities relating to generic drug price fixing and bid rigging and agreed to pay a $205.65 million criminal penalty (United States v. Taro Pharmaceuticals U.S.A., Inc., No. 20-cr-214, E.D. Pa.)....